ArticleFrontiers in oncology2026
Bisphosphonates in breast cancer radiotherapy: associations with skeletal complications and treatment outcomes - a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer is the most diagnosed cancer in women worldwide. Radiotherapy is a cornerstone of treatment for both early-stage ductal carcinoma Methods: We conducted a retrospective cohort study at the American University of Beirut Medical Center, including female patients aged 40-65 years with primary DCIS who received radiotherapy between November 2018 and September 2023. Data on patient demographics, tumor characteristics, treatment modalities, and outcomes were extracted from electronic medical records. Associations between BP use and pathologic fractures, musculoskeletal (MSK) complications, and treatment response were analyzed using logistic regression adjusted for relevant confounders. Results: Among 397 patients with breast cancer in our cohort, only 122 (30.7%) received ZOL. BP use was independently associated with increased odds of MSK complications (OR = 4.34; 95% CI: 2.42-7.77; p < 0.001) and pathologic fractures (OR = 2.93; 95% CI: 1.37-6.24; p = 0.005). No significant association was observed between BP use and tumor response, skin complications, fatigue, or other adverse effects. Conclusion: These findings likely reflect baseline skeletal fragility rather than a direct harmful effect of BPs. BPs remain an important indicator of bone vulnerability rather than a therapeutic modifier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.